It is a well-established principal that even the most promising API, monoclonal antibody or therapeutic peptide can only be turned into an effective and marketable drug if formulated in such a way that it reaches the blood stream and is bioavailable.
But, while this characteristic - bioavailability - has been the focus of lab scientists, clinical researchers and process developers’ efforts for many years, finding the solution that gives a particular drug the desired profile is still a major headache for pharmaceutical firms.
Similarly, biopharmaceutical firms hoping to develop oral delivery alternatives for injectable biologics will also need to work out how to ensure that their products are bioavailable, safe and effective.
Our virtual event will bring together expert regulators, academics and the drug industry scientists to define the challenges and share the latest research breakthroughs to help you make the decisions that will let you overcome your Bioavailability Challenge.
Role of excipients in design of solid amorphous drug dispersions for delivery of poorly water-soluble drugs - by Ashland
Divya Tewari - Ashland
Most new drug candidates suffer from poor water- solubility leading to rate limiting dissolution, slow...
Dow AFFINISOL™ polymers for Solubility Enhancement - by Dow Pharma & Food Solutions
Kevin O’Donnell - The Dow Chemical Company, William "Trey" Porter III - The Dow Chemical Company
Dow’s AFFINISOL™ line of excipients include AFFINISOL™ HMPCAS for spray drying applications and AFFINISOL™ HPMC...
How glass-forming polymers improve bioavailability / Enhanced oral bioavailability with Soluplus® – case study - by BASF SE
Felicitas Guth - BASF, Heiko Alexander Schiffter - BASF
How glass-forming polymers improve bioavailabilityPolymers are essential components of oral solid dosage forms and used...